{
    "clinical_study": {
        "@rank": "28499", 
        "arm_group": {
            "arm_group_label": "LY3009120", 
            "arm_group_type": "Experimental", 
            "description": "LY3009120 in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to see how safe the investigational drug known as\n      LY3009120 is and whether it will work to help people with advanced cancer or cancer that has\n      spread to other parts of the body."
        }, 
        "brief_title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neoplasms", 
            "Neoplasm Metastasis", 
            "Melanoma", 
            "Carcinoma, Non-Small-Cell Lung", 
            "Colorectal Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Colorectal Neoplasms", 
                "Melanoma", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced or metastatic cancer\n\n          -  Other available therapies have failed to cure the cancer\n\n          -  The cancer that has no proven effective therapy\n\n          -  The cancer can be biopsied (depending on the tumor type and/or the dose of drug\n             received, tumor biopsies may be required)\n\n          -  Able to swallow capsules\n\n        Exclusion Criteria:\n\n          -  Have active cancer in the brain or spinal cord\n\n          -  Have an active infection of any kind (fungal, viral, or bacterial)\n\n          -  Have a cancer of the blood\n\n          -  Are pregnant or breastfeeding\n\n          -  Have some types of eye problems or impairments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014116", 
            "org_study_id": "13873", 
            "secondary_id": "I6X-MC-JBDA"
        }, 
        "intervention": {
            "arm_group_label": "LY3009120", 
            "description": "Administered orally.", 
            "intervention_name": "LY3009120 capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 29, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial 1-877-CTLILLY or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose (MTD) of LY3009120", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 (28 Days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014116"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants with Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline through study completion (estimated as 37 months)"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1:  Predose up to 12 hours postdose (Cycle = 28 Days)"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3009120", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1:  Predose up to 12 hours postdose (Cycle = 28 Days)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}